Introduction {#sec1}
============

The incidence and mortality of cancer are increasing worldwide, and cancer has been a major human health problem that creates a large economic burden in both developed and undeveloped countries. According to reported statistics, there were approximately 1688780 new cancer diagnoses, and 600920 cases resulting in mortality due to malignant tumours in the United States in the year 2017 \[[@B1]\]. In 2015, there were nearly 4292000 new cancer diagnoses and 2814000 cancer-related deaths in China \[[@B2]\]. Although the underlying mechanism of carcinogenesis is not completely deciphered, a number of studies have demonstrated that the occurrence of cancer is a complicated process, which includes various environmental factors and genetic susceptibilities \[[@B3]\]. Accumulating evidence has shown that individual genetic susceptibility plays a significant role in the occurrence of a tumour. Moreover, the relationship between polymorphisms and cancer risk has been confirmed for many genes \[[@B4],[@B5]\]. Several lines of evidence have indicated that the progression of a tumour could be related to immunoevasion. Human leucocyte antigen (HLA) may play a critical role in the development and progression of cancer by mediating immune responses \[[@B6]\].

HLA-G, a non-classical HLA class I molecule, is known for its suppressive function and has seven different isoforms. Of the seven isoforms, four have membrane-bound forms (HLA-G1 to HLA-G4) and three have soluble forms (HLA-G5, HLA-G6, and HLA-G7) \[[@B7]\]. Differing from the classic HLA class I molecules, HLA-G is characterised by its restricted tissue distribution, low rate of polymorphism, and immunosuppressive properties \[[@B8]\]. The aberrant expression of HLA-G has been considered a mechanism in a wide variety of tumours that helps the tumour cells escape immunosurveillance \[[@B9]\]. HLA-G has been shown to act as a negative regulator of the human immune response by several mechanisms, including the inhibition of the cytotoxic effects of T lymphocytes and natural killer (NK) cells, as well as the prevention of antigen recognition and anti-proliferative responses of CD4^+^ T cells \[[@B10]\]. Accumulating evidence has shown that HLA-G is highly expressed in a variety of tumour tissues, including breast cancer \[[@B11]\], cervical cancer \[[@B12]\], hepatocellular carcinoma (HCC) \[[@B13]\], oesophageal carcinoma (EC) \[[@B14]\], thyroid carcinoma \[[@B15]\], lung cancer \[[@B14]\], gastric cancer \[[@B14]\], colorectal cancer (CRC) \[[@B14]\], and renal cell carcinoma \[[@B16]\]. These studies show that HLA-G may play a pivotal role in the occurrence and progression of malignant tumours.

The human *HLA-G* gene, comprising eight exons and seven introns, is located on chromosome 6p21.3. Several published studies have indicated that some polymorphisms of the *HLA-G* gene are related to cancer development \[[@B17]\]. The 14-bp insertion/deletion (*Ins/Del*) polymorphism in exon 8 of the 3′ untranslated region (3′UTR) of *HLA-G* is the most widely studied polymorphism. It has been demonstrated that the *HLA-G* 3′UTR 14-bp *Ins/Del* variation implicates the stability and isoform splicing patterns of *HLA-G* mRNA \[[@B18]\]. The *Ins* allele is associated with the decreased expression of HLA-G, while the *Del* allele is associated with the increased expression of HLA-G \[[@B19]\]. After Castelli et al. \[[@B20]\] first assessed the correlation between the *HLA-G* 14-bp *Ins/Del* variation and bladder cancer in 2008, a growing number of molecular epidemiological case--control studies have been carried out in different populations to investigate the association of the *HLA-G* 14-bp *Ins/Del* variant with different types of cancers \[[@B11],[@B13],[@B21]\]. However, the results of the published articles varied and even contradicted each other. To identify these findings, four meta-analyses of the association between the *HLA-G* 14-bp *Ins/Del* variation and cancer risk were carried out several years ago \[[@B25]\]. Although all four meta-analyses reached the same conclusion, that there was no relationship between the *HLA-G* 14-bp *Ins/Del* polymorphism and the risk of overall cancer, the results of their stratified analyses were inconsistent. Due to the relatively small sample sizes included in the previous meta-analyses, all these meta-analyses lacked sufficient statistical power. Since these reports, many new case--control studies have explored the correlation between the *HLA-G* 14-bp *Ins/Del* polymorphism and the risk of different types of cancer; however, the results of these subsequent studies were still inconclusive. Therefore, an updated meta-analysis including all of the currently identified studies was performed to explore the precise association of the *HLA-G* 14-bp *Ins/Del* polymorphism with cancer susceptibility.

Materials and methods {#sec2}
=====================

Search strategy {#sec2-1}
---------------

A systematic literature search with no language limitation was conducted in PubMed, Web of Science, CNKI, VIP, and Wanfang databases to obtain all eligible studies published before 28 January 2019. The relevant search keywords included: (HLA-G OR 'Human leukocyte antigen-G') AND (mutation OR polymorphism OR genotype OR variation) AND (carcinoma OR cancer OR malignancy OR adenocarcinoma OR neoplasm OR neoplasia OR tumour OR tumour). In addition, other relevant articles were acquired by searching the reference lists of the reviews and studies selected from the search parameters described above.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Published articles fulfilling the following criteria were included: (i) articles published in English or Chinese; (ii) studies that evaluated the correlation between *HLA-G* 14-bp *Ins/Del* polymorphism and cancer risk; (iii) studies that designed as case--control or cohort studies; and (iv) studies that contained sufficient data for genotype distribution estimation or the overall odds ratio (ORs) and 95% confidence intervals (CIs). Articles were excluded based on the following criteria: (i) case reports, not case--control studies, letters, comment articles, reviews or meta-analyses; (ii) lacking sufficient data; and (iii) duplicated publications or samples.

Data extraction {#sec2-3}
---------------

Two investigators (Y.J. and J.L.) independently collected data from the eligible articles in accordance with the inclusion criteria above. Data extracted from all of the selected studies included the following information: the first author, publication year, country, study population ethnicity, cancer type, sources of controls, genotyping method, number of cases and controls for the 14-bp *Ins/Del* genotypes of *HLA-G*, and results of the Hardy--Weinberg equilibrium (HWE) test in controls. In cases of inconsistent evaluations, all investigators were consulted to obtain a consensus of inclusion or exclusion of the study in the present meta-analysis.

Methodological quality assessment {#sec2-4}
---------------------------------

The quality of the included studies was appraised according to the Newcastle--Ottawa Scale (NOS) by two independent investigators. Each study had a calculated score based on three criteria including selection, comparability, and exposure (maximum score = 9 points). The score of a study must be higher than 5 to be included in the present meta-analysis (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>) \[[@B29]\]. Any discrepancies were settled by all investigators through discussion.

Statistical analysis {#sec2-5}
--------------------

We conducted this meta-analysis based on the checklists and guidelines according to PRISMA \[[@B30]\]. The HWE was assessed for each study in the control groups using a Chi-square test, and every study with a calculated *P* less than 0.05 was considered a significant disequilibrium. ORs with 95% CIs were adopted to assess the strength of the relationship between the *HLA-G* 14 bp *Ins/Del* polymorphism and the risk of cancer in the homozygote comparisons (*Ins/Ins vs. Del/Del*), heterozygote comparisons (*Ins/Del vs. Del/Del*), dominant model (*Ins/Del + Ins/Ins vs. Del/Del*), recessive model (*Ins/Ins vs. Ins/Del + Del/Del*), and allelic comparisons (*Ins vs. Del*). Stratified analyses were carried out based on ethnicity (Asian, African, Caucasian, and Mixed population), type of cancer (publication with only one case--control study was merged as 'other cancers'), and source of controls (hospital-based and population-based (PB)). Differences based on a Z-test were regarded as statistically significant if the *P*\<0.05. The heterogeneity within each study was measured by a Cochran's Q statistical test and the *I^2^* test \[[@B31]\]. A random-effects model was applied to measure the pooled OR when the *I^2^* value \> 50%. Otherwise, a fixed-effects model was adopted according to the heterogeneity \[[@B32]\]. Sensitivity analysis was performed to assess the effect of each study on the pooled OR by removing each publication one by one to examine the stability of the overall results. Begg's funnel plot test and Egger's tests were applied to assess the potential publication bias \[[@B33],[@B34]\]. All statistical analyses were conducted by STATA 12.0 software (version 12.0; STATA Corp. College Station, TX, U.S.A.). All of the tests were two-sided, and a *P*-value \<0.05 was accepted as statistically significant.

Results {#sec3}
=======

Characteristics of eligible studies {#sec3-1}
-----------------------------------

[Figure 1](#F1){ref-type="fig"} demonstrates the flow chart of the study selection process. After a systematic literature search in the databases mentioned above and a manual search in other sources, a total of 146 candidate articles were acquired. Eighteen search results were excluded as duplicates. Of the remaining 128 articles, 84 were removed after examining the titles and abstracts, resulting in a total of 44 articles. Among the 81 excluded studies, 52 were studies that were obviously irrelevant, 25 were not related to cancer, and 7 were reviews or meta-analyses. After carefully viewing the full text of the 44 potential studies to include in the meta-analysis, 19 of them were removed based on the following reasons: 3 did not have sufficient data, 5 were not case--control studies, 2 data were covered by other studies, and 9 were not relevant to the *HLA-G* 14 bp *Ins/Del* polymorphism. Finally, the remaining 25 eligible studies were included in the meta-analysis according to the inclusion and exclusion criteria \[[@B11],[@B13],[@B20],[@B35]\]. A total of 4981 cases and 6391 controls are included in the current meta-analysis. The characteristics of the included case--control studies are displayed in [Table 1](#T1){ref-type="table"}. All studies were published between 2008 and 2018. With the exception of two publications reported in Chinese, all studies were written in English. Among all 25 studies, 10 studies were conducted in Asian populations, 7 in Caucasian populations, 6 in Mixed populations, and 2 in African populations. There were 11 different types of tumours in our study including: EC (*n*=2), non-small cell lung cancer (NSCLC) (*n*=2), breast cancer (*n*=5), cervical cancer (*n*=4), HCC (*n*=3), non-Hodgkin's lymphoma (NHL) (*n*=2), thyroid cancer (*n*=2), prostate cancer (*n*=1), CRC (*n*=1), head and neck squamous cell carcinoma (HNSCC) (*n*=1), neuroblastoma (*n*=1), and bladder cancer (*n*=1). There were 12 PB studies and 13 hospital-based studies. All included studies used polymerase chain reaction (PCR) as the genotyping method with the exception of one study \[[@B39]\] that used DNA-PAGE. With the exception of one study \[[@B42]\], the genotype distributions of controls in all eligible studies did not deviate from the HWE. The distribution of genotypes and allele frequencies of the *HLA-G* 14 bp *Ins/Del* polymorphism in the cases and controls are provided in [Table 2](#T2){ref-type="table"}. Supplementary Table 1 demonstrated that the included studies were reliable based on the methodological quality.

![The flow diagram of the included and excluded studies](bsr-39-bsr20181991-g1){#F1}

###### Characteristics of eligible case--control studies included in this meta-analysis

  First author                              Year   Country     Ethnicity   Cancer Type       Source of controls   Genotyping method   Number (case/control)   HWE   NOS score
  ----------------------------------------- ------ ----------- ----------- ----------------- -------------------- ------------------- ----------------------- ----- -----------
  Gao et al. \[[@B21]\]                     2011   China       Asian       EC                HB                   PCR                 132/254                 Yes   6
  Xu et al. \[[@B35]\]                      2017   China       Asian       NSCLC             PB                   PCR                 113/150                 Yes   8
  Zidi et al. \[[@B36]\]                    2016   Tunisia     African     Breast cancer     PB                   PCR                 104/83                  Yes   8
  Zambra et al. \[[@B37]\]                  2016   Brazil      Mixed       Prostate cancer   HB                   PCR                 187/129                 Yes   7
  Yang et al. \[[@B22]\]                    2014   Taiwan      Asian       Cervical cancer   HB                   PCR                 315/400                 Yes   7
  Silva et al. \[[@B38]\]                   2013   Brazil      Mixed       Cervical cancer   HB                   PCR                 55/50                   Yes   7
  Agnihotri et al. \[[@B39]\]               2017   India       Asian       HNSCC             PB                   DNA-PAGE            383/383                 Yes   8
  Wisniewski et al. \[[@B40]\]              2015   Poland      Caucasian   NSCLC             PB                   PCR                 319/465                 Yes   8
  Teixeira et al. \[[@B41]\]                2013   Brazil      Mixed       HCC               PB                   PCR                 109/202                 Yes   7
  Haghi et al. \[[@B42]\]                   2015   Iran        Asian       Breast cancer     PB                   PCR                 227/255                 No    7
  Garziera et al. \[[@B43]\]                2016   Italy       Caucasian   CRC               PB                   PCR                 308/294                 Yes   8
  Chen et al. \[[@B44]\]                    2012   China       Asian       EC                HB                   PCR                 239/467                 Yes   7
  Tawfeek et al. \[[@B45]\]                 2018   Egypt       African     NHL               PB                   PCR                 150/100                 Yes   8
  Dardano et al. \[[@B23]\]                 2012   Italy       Caucasian   Thyroid cancer    HB                   PCR                 183/245                 Yes   7
  Ramos et al. \[[@B11]\]                   2014   Brazil      Mixed       Breast cancer     HB                   PCR                 80/191                  Yes   7
  Eskandari-Nasab et al. \[[@B46]\]         2013   Iran        Asian       Breast cancer     PB                   PCR                 236/203                 Yes   8
  Lau et al. \[[@B24]\]                     2011   Australia   Caucasian   Neuroblastoma     PB                   PCR                 153/404                 Yes   8
  Kim et al. \[[@B47]\]                     2013   Korea       Asian       HCC               HB                   PCR                 270/91                  Yes   7
  Jiang et al. \[[@B13]\]                   2011   China       Asian       HCC               PB                   PCR                 318/599                 Yes   8
  Jeong et al. \[[@B48]\]                   2014   Korea       Asian       Breast cancer     HB                   PCR                 80/80                   Yes   7
  Ferguson et al. \[[@B49]\]                2012   Canada      Caucasian   Cervical cancer   HB                   PCR                 539/833                 Yes   7
  Bortolotti et al. \[[@B50]\]              2014   Italy       Caucasian   Cervical cancer   HB                   PCR                 100/100                 Yes   7
  Castelli et al. \[[@B20]\]                2008   Brazil      Mixed       Bladder cancer    PB                   PCR                 80/107                  Yes   8
  Bielska et al. \[[@B51]\]                 2015   Poland      Caucasian   NHL               HB                   PCR                 207/150                 Yes   7
  de Figueiredo-Feitosa et al. \[[@B52]\]   2017   Brazil      Mixed       Thyroid cancer    PB                   PCR                 94/156                  Yes   8

Abbreviation: HB, hospital-based.

###### *HLA-G* 14--bp *Ins/Del* polymorphism genotype distribution and allele frequency in cases and controls

  First author                              Year   Genotype (*n*)   Allele frequency (*n*)   HWE                                                         
  ----------------------------------------- ------ ---------------- ------------------------ ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -------
  Gao et al. \[[@B21]\]                     2011   132              54                       66    12    254   77    128   46    174   90    282   220   0.852
  Xu et al. \[[@B35]\]                      2017   113              52                       44    17    150   51    75    24    148   78    177   123   0.919
  Zidi et al. \[[@B36]\]                    2016   104              31                       52    20    83    20    42    20    114   92    82    82    0.975
  Zambra et al. \[[@B37]\]                  2016   187              85                       83    19    129   45    58    26    253   121   148   110   0.656
  Yang et al. \[[@B22]\]                    2014   315              169                      110   36    400   188   176   36    448   182   552   248   0.850
  Silva et al. \[[@B38]\]                   2013   55               11                       29    15    50    19    19    12    51    59    57    43    0.283
  Agnihotri et al. \[[@B39]\]               2017   383              82                       212   89    383   122   175   86    376   390   419   347   0.876
  Wisniewski et al. \[[@B40]\]              2015   319              111                      160   48    465   157   231   77    382   256   545   385   0.311
  Teixeira et al. \[[@B41]\]                2013   109              49                       44    16    202   70    87    45    142   76    227   177   0.205
  Haghi et al. \[[@B42]\]                   2015   227              56                       127   44    255   52    154   49    239   215   258   252   0.004
  Garziera et al. \[[@B43]\]                2016   308              97                       138   73    294   114   122   58    332   284   350   238   0.059
  Chen et al. \[[@B44]\]                    2012   239              86                       123   30    467   155   237   70    295   183   547   377   0.412
  Tawfeek et al. \[[@B45]\]                 2018   150              40                       102   8     100   18    44    38    182   118   80    120   0.707
  Dardano et al. \[[@B23]\]                 2012   183              47                       96    40    245   84    110   51    190   176   278   212   0.409
  Ramos et al. \[[@B11]\]                   2014   80               18                       54    8     191   57    98    36    90    70    212   170   0.867
  Eskandari-Nasab et al. \[[@B46]\]         2013   236              80                       106   50    203   49    91    63    266   206   189   217   0.368
  Lau et al. \[[@B24]\]                     2011   153              66                       58    29    404   146   194   64    190   116   486   322   0.973
  Kim et al. \[[@B47]\]                     2013   270              159                      93    18    91    61    28    2     411   129   150   32    0.841
  Jiang et al. \[[@B13]\]                   2011   318              187                      113   18    599   304   241   54    487   149   849   349   0.822
  Jeong et al. \[[@B48]\]                   2014   80               54                       21    5     80    44    32    4     129   31    120   40    0.837
  Ferguson et al. \[[@B49]\]                2012   539              184                      242   113   833   272   399   162   610   468   943   723   0.770
  Bortolotti et al. \[[@B50]\]              2014   100              49                       40    11    100   38    40    22    138   62    116   84    0.201
  Castelli et al. \[[@B20]\]                2008   80               28                       37    15    107   35    50    22    93    67    120   94    0.868
  Bielska et al. \[[@B51]\]                 2015   207              49                       91    67    150   33    89    28    189   225   155   145   0.071
  de Figueiredo-Feitosa et al. \[[@B52]\]   2017   94               34                       47    13    156   61    65    30    115   73    187   125   0.255

Meta-analysis results {#sec3-2}
---------------------

The relationship between the *HLA-G* 14 bp *Ins/Del* polymorphism and cancer risk was assessed. The results revealed that the *HLA-G* 14 bp *Ins/Del* polymorphism was significantly associated with cancer risk in the homozygote comparison (*Ins/Ins vs. Del/Del*: OR = 0.80, CI = 0.64--1.00; *P*=0.049, [Figure 2](#F2){ref-type="fig"} and [Table 3](#T3){ref-type="table"}) and allelic comparison (*Ins vs. Del*: OR = 0.89, CI = 0.81--0.99; *P*=0.035, [Figure 3](#F3){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). However, no significant association with cancer risk was found in other models including: *Ins/Del vs. Del/Del*: OR = 0.93, CI = 0.81--1.06; *P*=0.267; *Ins/Del + Ins/Ins vs.Del/Del*: OR = 0.82, CI = 0.68--1.01; *P*=0.056; and *Ins/Ins vs. Ins/Del + Del/Del*: OR = 0.89, CI = 0.78--1.02; *P*=0.107 ([Table 3](#T3){ref-type="table"}). The random-effects model was used due to the significant heterogeneity of the included studies.

![Forest plots of the *HLA-G* 14-bp *Ins/Del* polymorphism and cancer risk (homozygote comparisons: *Ins/Ins vs. Del/Del*)](bsr-39-bsr20181991-g2){#F2}

![Forest plots of the *HLA-G* 14--bp *Ins/Del* polymorphism and cancer risk (allelic comparisons: *Ins vs. Del*)](bsr-39-bsr20181991-g3){#F3}

###### Analysis of the *HLA-G* 14 bp *Ins/Del* polymorphism and risk of cancer

  Variables           *n*   Homozygote (Ins/Ins vs. Del/Del)   Heterozygote (Ins/Del vs. Del/Del)   Dominant (Ins/Del + Ins/Ins vs. Del/Del)   Recessive (Ins/Ins vs. Ins/Del + Del/Del)   Allelic (Ins vs. Del)                                                                   
  ------------------- ----- ---------------------------------- ------------------------------------ ------------------------------------------ ------------------------------------------- ----------------------- ------- ----------------------- ------- ----------------------- -------
  Total               25    **0.80 (0.64--1.00)**              0.000                                0.93 (0.81--1.06)                          0.000                                       0.82 (0.68--1.01)       0.000   0.89 (0.78--1.02)       0.000   **0.89 (0.81--0.99)**   0.000
  Ethnicity                                                                                                                                                                                                                                                                        
  Asian               10    0.81 (0.58--1.12)                  0.003                                0.84 (0.67--1.06)                          0.001                                       0.87 (0.74--1.02)       0.068   0.83 (0.66--1.04)       0.000   0.87 (0.75--1.02)       0.001
  African             2     0.25 (0.04--1.62)                  0.003                                0.92 (0.57--1.48)                          0.585                                       0.26 (0.03--2.08)       0.000   0.67 (0.43--1.05)       0.641   0.59 (0.32--1.08)       0.026
  Mixed               6     **0.67 (0.49--0.92)**              0.146                                1.11 (0.77--1.59)                          0.060                                       **0.64 (0.48--0.86)**   0.489   0.99 (0.69--1.43)       0.034   **0.85 (0.72--0.99)**   0.083
  Caucasian           7     1.09 (0.91--1.29)                  0.084                                0.96 (0.77--1.19)                          0.044                                       1.12 (0.87--1.43)       0.039   0.99 (0.81--1.21)       0.053   1.03 (0.90--1.19)       0.035
  Type of cancer                                                                                                                                                                                                                                                                   
  EC                  2     0.56 (0.28--1.15)                  0.104                                0.86 (0.65--1.13)                          0.409                                       **0.66 (0.45--0.96)**   0.156   0.80 (0.61--1.03)       0.223   **0.81 (0.67--0.97)**   0.118
  NSCLC               2     0.83 (0.57--1.20)                  0.583                                0.79 (0.47--1.31)                          0.094                                       0.90 (0.64--1.23)       0.918   0.80 (0.51--1.23)       0.124   0.90 (0.75--1.07)       0.288
  Breast cancer       5     **0.65 (0.48--0.89)**              0.656                                0.82 (0.65--1.05)                          0.108                                       **0.74 (0.57--0.96)**   0.346   **0.77 (0.61--0.97)**   0.201   **0.82 (0.70--0.94)**   0.423
  Other cancers       5     1.00 (0.64--1.58)                  0.009                                1.04 (0.70--1.56)                          0.002                                       1.03 (0.84--1.26)       0.082   1.03 (0.70--1.52)       0.001   0.99 (0.78--1.26)       0.004
  Cervical cancer     4     0.94 (0.62--1.54)                  0.068                                0.90 (0.64--1.26)                          0.061                                       1.06 (0.85--1.32)       0.127   0.90 (0.65--1.24)       0.054   0.94 (0.74--1.18)       0.052
  HCC                 3     0.75 (0.34--1.65)                  0.057                                0.83 (0.67--1.04)                          0.195                                       0.78 (0.40--1.53)       0.103   0.85 (0.56--1.30)       0.042   0.88 (0.59--1.31)       0.012
  NHL                 2     0.40 (0.03--6.47)                  0.000                                0.81 (0.53--1.22)                          0.336                                       0.45 (0.02--9.65)       0.000   0.77 (0.52--1.14)       0.316   0.75 (0.26--2.15)       0.000
  Thyroid cancer      2     1.15 (0.74--1.79)                  0.223                                1.26 (0.84--1.90)                          0.616                                       0.92 (0.63--1.36)       0.291   1.35 (0.97--1.88)       0.407   1.11 (0.89--1.39)       0.294
  Source of control                                                                                                                                                                                                                                                                
  HB                  12    0.90 (0.68--1.23)                  0.002                                0.94 (0.77--1.14)                          0.012                                       0.91 (0.67--1.23)       0.001   0.93 (0.77--1.12)       0.009   0.94 (0.81--1.09)       0.001
  PB                  13    **0.72 (0.53--0.99)**              0.000                                0.92 (0.75--1.12)                          0.003                                       **0.76 (0.58--1.00)**   0.000   0.86 (0.71--1.05)       0.000   **0.85 (0.73--0.99)**   0.000

Significant results (*P*\<0.05) are highlighted in bold. Abbreviation: HB, hospital-based.

In the stratified analysis shown in [Table 3](#T3){ref-type="table"}, we explored the association between the *HLA-G* 14-bp *Ins/Del* variation and cancer risk in different ethnicities. The results showed a decreased cancer risk in Mixed populations based on three genetic models (*Ins/Ins vs. Del/Del*: OR = 0.67, CI = 0.49--0.92, *P*=0.014; *Ins/Del + Ins/Ins vs.Del/Del*: OR = 0.64, CI = 0.48--0.86, *P*=0.003; and *Ins vs. Del*: OR = 0.85, CI = 0.72--0.99, *P*=0.034). In a stratified analysis based on the cancer types, we found that the *HLA-G* 14-bp *Ins/Del* polymorphism was significantly associated with a reduced EC risk in the dominant model (*Ins/Del + Ins/Ins vs.Del/Del*: OR = 0.66, CI = 0.45--0.96, *P*=0.029) and in the allelic comparisons model (*Ins vs. Del*: OR = 0.81, CI = 0.67--0.97, *P*=0.022). Similar results were found in breast cancer based on all genetic models except for the heterozygote comparisons (*Ins/Ins vs. Del/Del*: OR = 0.65, CI = 0.48--0.89, *P*=0.007; *Ins/Del + Ins/Ins vs.Del/Del*: OR = 0.74, CI = 0.57--0.96, *P*=0.022; *Ins/Ins vs. Ins/Del + Del/Del*: OR = 0.77, CI = 0.61--0.97, *P*=0.024; and *Ins vs. Del*: OR = 0.82, CI = 0.70--0.94, *P*=0.006). In subgroups formed according to source of the controls, significantly decreased risks were observed in the PB analysis in the homozygote comparisons model (*Ins/Ins vs. Del/Del*: OR = 0.72, CI = 0.53--0.99, *P*=0.047), the dominant model (*Ins/Del + Ins/Ins vs.Del/Del*: OR = 0.76, CI = 0.58--1.00, *P*=0.048) and the allelic comparisons model (*Ins vs. Del*: OR = 0.85, CI = 0.73--0.99, *P*=0.040).

Test of heterogeneity {#sec3-3}
---------------------

A *Q* test and *I^2^* statistic were assessed to evaluate the heterogeneity among the selected studies. High heterogeneity was observed across studies, as well as in some subgroup analyses, as tested by random-effects analysis. Moreover, we evaluated the heterogeneity of all genetic models in regard to different ethnicities, cancer types, and the source of the controls. However, the observed heterogeneity could not be completely explained by different ethnicities, types of cancer, or the source of the controls (data not shown).

Sensitivity analyses {#sec3-4}
--------------------

Sensitivity analysis was carried out to examine the influence of each eligible study on the pooled ORs by the sequential removal of each individual study form the analysis. The individual removal procedure affected the pooled ORs, indicating the instability and unreliability of our findings for the homozygote comparisons ([Figure 4](#F4){ref-type="fig"}). Sensitivity analyses of other genetic models yielded similar results (Supplementary Figure S1).

![Sensitivity analysis of the *HLA-G* 14-bp *Ins/Del* polymorphism and cancer risk (homozygote comparisons: *Ins/Ins vs. Del/Del*)](bsr-39-bsr20181991-g4){#F4}

Publication bias {#sec3-5}
----------------

Begg's and Egger's tests were conducted to explore the potential for publication bias in assessment of the relationship between the *HLA-G* 14 *Ins/Del* polymorphism and cancer risk in all genetic models. No asymmetry was observed in the Begg's funnel plots, and neither Begg's rank correlation nor Egger's regression showed publication bias among the studies ([Figure 5](#F5){ref-type="fig"} and Supplementary Table S2).

![Funnel plot assessing evidence of publication bias (homozygote comparisons: *Ins/Ins vs. Del/Del*)](bsr-39-bsr20181991-g5){#F5}

Discussion {#sec4}
==========

A well-characterised distinguishing feature of malignant tumours is their ability to evade antitumour immune destruction, which has proven to be a major contributor to tumorigenesis \[[@B53]\]. HLA-G is an important complex molecule that plays an important role in facilitating tumour escape from immune surveillance by its immunosuppressive function on T and NK cells \[[@B10]\], and the aberrant expression of HLA-G has been reported to be related to a variety of tumours \[[@B11]\]. The expression level of the HLA-G protein is related to *HLA-G* gene polymorphisms. The *Ins* allele has been shown to decrease the expression of HLA-G, and the *Del* allele has been shown to elevate the expression of HLA-G \[[@B19]\]. To date, a number of studies have explored the relationship between the *HLA-G* gene polymorphisms and the risk of cancer. Among the *HLA-G* gene polymorphisms, the *HLA-G* 14-bp *Ins/Del* polymorphism is the most widely explored. Up to now, multiple published case--control studies have investigated the underlying correlation between the *HLA-G* 14-bp *Ins/Del* polymorphism and cancer risk. However, the biological role of the *HLA-G* 14-bp *Ins/Del* polymorphism in the development of cancer remains poorly understood. Considering the inconsistent or even contradictory previously published results, and the fact that individual case--control studies may have been statistically underpowered, we assessed the effect of the polymorphism in the risk of cancer in the present meta-analysis. The present analysis includes all eligible studies to precisely explore the association of the *HLA-G* 14-bp *Ins/Del* polymorphism with cancer susceptibility.

In this meta-analysis, we evaluated the *HLA-G* 14-bp *Ins/Del* polymorphism and cancer risk relationship with all qualified case--control studies. In total, 4981 cases and 6391 controls were included. By quantificatively analysing the integrated data, the results of our present meta-analysis revealed that the *HLA-G* 14-bp *Ins/Del* polymorphism is significantly associated with the susceptibility of overall cancer. There were a larger number of studies that had evaluated the correlation between the *HLA-G* 14-bp *Ins/Del* polymorphism and the susceptibility to different types of cancer. However, the conclusions were paradoxical. Gao et al. \[[@B21]\] carried out a case--control study and found that the *HLA-G* 14-bp *Ins/Del* variant was associated with an elevated risk of EC. Similar results were found in other types of cancer, including thyroid cancer \[[@B52]\], breast cancer \[[@B46]\], and cervical cancer \[[@B22]\], among others. However, a few studies reported the opposite result, that the *HLA-G* 14-bp *Ins/Del* polymorphism could decrease the risk of some types of cancer. Additionally, some studies showed that the *HLA-G* 14-bp *Ins/Del* polymorphism did not play a role in cancer susceptibility. Furthermore, results from studies on the correlation between the *HLA-G* 14-bp *Ins/Del* polymorphism in the same types of cancer were inconsistent. For example, the study conducted by Teixeira et al. \[[@B41]\] demonstrated that individuals with the *HLA-G* 14-bp *Ins/Del* polymorphism had significantly increased risk for the occurrence of HCC, while Kim et al. \[[@B47]\] showed no relationship between the *HLA-G* 14-bp *Ins/Del* variant and HCC susceptibility; however, Jiang et al. \[[@B13]\] indicated that this variation may actually be a protective factor in HCC susceptibility. To address this controversy and to obtain a more accurate conclusion, several meta-analyses have been carried out several years ago \[[@B25]\]. Inconsistent with our present study, all of the previous meta-analyses reached the same conclusion: there was no relationship between the *HLA-G* 14-bp *Ins/Del* polymorphism and the risk of overall cancer. A latest meta-analysis of 21 published case--control studies with 3815 cases and 5802 controls was performed by Almeida et al. in 2018 \[[@B54]\]; however, they assessed the relationship between the *HLA-G* 14 bp *Ins/Del* polymorphism and the risk of cancer only in the allelic comparisons (*Ins vs. Del*), and no positive results were found. Our results demonstrated, for the first time, a significant relationship between the *HLA-G* 14-bp *Ins/Del* polymorphism and a decreased overall cancer risk. Compared with previous meta-analyses, our study included a larger sample size, a wider variety of cancer types, and a more diverse sample population. Hence, our results are persuasive based on their adequate statistical power.

Significant heterogeneity among the studies was shown in our results; we performed stratified analyses in terms of ethnicity, types of cancer, and sources of controls. In the subgroup analysis based on ethnicity, an obviously decreased cancer susceptibility was demonstrated in Mixed populations alone but not in Asian, African, or Caucasian populations. This discrepancy in cancer risk may be interpreted by geographic climate, daily lifestyle, ethnic diversity, dietary habits, as well as differences in alleles and genotypes in various ethnic populations. When carrying out stratified analysis by cancer type, we found that the *HLA-G* 14 bp *Ins/Del* polymorphism was significantly associated with a reduced EC and breast cancer risk, but we failed to find a significant risk association in other types of cancer. This result may be explained by the inherent heterogeneity of tumorigenic development in diverse cancer types \[[@B55]\]. Due to the relatively small sample size of each cancer type, inadequate statistical power may also be a factor in lacking a significant polymorphism--cancer risk relationship in these other cancer types. When we evaluated the *HLA-G* 14-bp *Ins/Del* polymorphism--cancer risk association according to source of the control, a significantly decreased risk was observed in PB controls but not in hospital-based controls; this result further verifies that the *HLA-G* 14-bp *Ins/Del* polymorphism is a potential protective factor for cancer. Previously, published meta-analyses also performed subgroup analysis to explore the association between the *HLA-G* 14 bp *Ins/Del* variant and risk of developing cancer; some significant results were reported and are partially in line with the conclusions from our present study. Zhang and Wang \[[@B25]\] conducted a meta-analysis in 2014 and found that the polymorphism was associated with risk of developing HCC in a subgroup analysis by cancer type. This finding was not in accordance with our result; however, only two case--control studies of HCC were included in their study. Li et al. \[[@B26]\] revealed a significant association between the *HLA-G* 14 bp *Ins/Del* variant and both breast cancer and PB control subgroup analyses, which is in agreement with the conclusions from our study. In 2015, Ge et al. \[[@B28]\] demonstrated the significant association in Asian populations and in breast cancer subgroups in stratified analyses. Inconsistent with their results, we found no association between the *HLA-G* 14 bp *Ins/Del* polymorphism and cancer risk in Asian populations in the present study. However, compared with their meta-analysis that included only six case--control studies on Asian populations, the results of our study, which involved ten case--control trials, have more adequate and more robust statistical power.

Despite our efforts to assess the association between the *HLA--G* 14--bp *Ins/Del* variant and the risk of cancer, there are several limitations we must account for in the present meta-analysis that may impact the objectivity of the findings. First, only unadjusted estimates were used to assess the strength of the relationship between the *HLA--G* 14--bp *Ins/Del* variant and the risk of developing cancer. The analysis cannot account for confounding factors such as life habit, environment factors, gene--gene interactions, gene--environment interactions, and even different variant loci in the same gene factors. Second, there may be a selection bias in our study, since only published case--control studies written in Chinese or English were included in our meta-analysis. Some potential eligible studies may have been excluded, because they were not detected, published, or because they were written in other languages. Third, although the total sample sizes of our meta-analysis were relatively large, the sample sizes of some stratified analyses were extremely small. There were not enough appropriate studies in some subgroups, weakening the statistical power to investigate the real relationship between the *HLA-G* 14-bp *Ins/Del* polymorphism and cancer risk. Fourth, because of the high heterogeneity in our present meta-analysis, the reliability of the findings may be weakened. Despite the application of the random-effects model in our meta-analysis, the findings on the overall cancer susceptibility should be taken cautiously. Fifth, the result of our meta-analysis should be interpreted with caution and needs to be confirmed by more case--control studies, because the sensitivity analyses indicated that deletion of certain individual study had an impact on the reliability of our results. Larger sample sizes and well-designed case--control experiments with various types of cancer in diverse ethnicities are needed to further verify the relationship between the *HLA--G* 14-bp *Ins/Del* variant and cancer risk.

In summary, the pooled results of our meta-analysis demonstrated that the *HLA--G* 14-bp *Ins/Del* polymorphism may play an important role in decreasing cancer susceptibility, especially in breast cancer and oesophageal cancer (EC), in the Mixed populations. The results allowed us to hypothesise that the *HLA--G* 14-bp *Ins/Del* variant may be a potential protective factor of cancer. Larger sample sizes and well-designed case--control experiments with various types of cancer in different ethnicities are needed to further verify our findings.
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CI

:   confidence interval

CRC

:   colorectal cancer

EC

:   oesophageal cancer/carcinoma

HCC

:   hepatocellular carcinoma

HLA

:   human leucocyte antigen

HWE

:   Hardy--Weinberg equilibrium

Ins/Del

:   insertion/deletion

NK

:   natural killer

OR

:   odds ratio

PB

:   population-based

3′UTR

:   3′ untranslated region
